Luyan Pharmaceutical Co., Ltd.

Legal Opinion for the 2025 Annual Shareholders' Meeting

Fujian Xinshi Law Firm provides a legal opinion on Yanshan Pharmaceutical Co., Ltd.'s 2025 Annual Shareholders' Meeting. The opinion confirms the meeting's invitation and procedures comply with regulations and the company's Articles of Association. It also validates shareholder eligibility, with 632 shareholders representing 39.6132% of total shares eligible to attend. The firm concludes the meeting will be valid and effective.

Announcement of Resolutions of the 2025 Annual Shareholders' Meeting

The 2025 Annual Shareholders' Meeting was held on May 12, 2026. The meeting's purpose was to approve the 2025 annual reports and financial plans. Key figures show overwhelming support for all resolutions, with voting results consistently above 99.64% 'For'. Material outcomes include the approval of the Board of Directors' and Supervisory Board's 2025 annual reports, the 2025 financial report, and the 2025 and 2026 annual budget and financial management plans.

Announcement on Participation in the 2025 Annual Report Performance Briefing and Investor Online Reception Day

The company announced its participation in the 2025 Annual Report Performance Briefing and Investor Online Reception Day on May 15, 2026. This event, organized with the Xiamen Securities Regulatory Bureau, aims to enhance investor communication. Key participants will include the Chairman, an Independent Director, and the CFO. Investors can join online via the "Investor Relations" website, WeChat, or a financial information APP.

Independent Director 2025 Annual Work Report (Ye Shaoqin)

This report details the 2025 work of Independent Director Ye Shaoqin. The director attended 4 board meetings and 2 special committee meetings (Audit and Nomination). Key activities included ensuring compliance with regulations, protecting minority shareholder rights, and engaging in on-site investigations. The director plans to enhance shareholder communication and improve corporate governance in the future.

Independent Director's 2025 Annual Work Report (Wu Junlong)

This report details the independent director's 2025 work, focusing on corporate governance and financial oversight. The director attended all 4 board meetings and 1 shareholder meeting, actively participating in discussions and providing guidance. Key activities included reviewing financial reports, ensuring compliance, enhancing internal controls, and protecting minority shareholder rights. The director also conducted field investigations to assess company operations and regulatory adherence, aiming for sustainable development.

Independent Director's 2025 Annual Report (Song Peilin)

Notice of Online Performance Briefing for 2025 Annual Report

2025 Internal Control Audit Report

This report details the internal control audit of [Company Name] for the period ending December 31, 2025. The audit was conducted according to the "Guidelines for Internal Control Audits." The registered accountants assessed risks and provided recommendations. The key outcome is the opinion that the Company maintained effective internal controls over financial reporting as of December 31, 2025, in accordance with all relevant regulations.

2025 Annual Internal Control Rules Implementation Self-Examination Form

This document is a self-examination form for the implementation of internal control rules for 2025. The purpose is to assess the company's adherence to internal control, information disclosure, financial control, and regulatory compliance. Key figures indicate that all examined items, including staffing, fund usage, risk management, and financial reporting, were answered with 'Yes' or 'Not Applicable'. The material outcome is that the company's internal control system is deemed effective, meets regulatory requirements, and demonstrates appropriate management of related party transactions and satisfactory financial management.

2025 Internal Control Self-Assessment Report

Compensation and Assessment Management System for Senior Management Personnel

This document establishes a compensation and assessment management system for senior management personnel to enhance operational efficiency. Compensation is determined by base salary, bonus, and a performance adjustment factor (0%-5%) linked to company performance. Key figures include compensation ranges for General Managers (6.10 ten thousand yuan), Deputy General Managers (2.57 ten thousand yuan), and Financial Supervisors (2.50 ten thousand yuan). The system aims to align compensation with company performance and market conditions, subject to committee approval and board ratification.

Remuneration Management System for Directors

This document establishes a remuneration management system for company directors to clarify responsibilities and enhance governance. The system aligns director pay with operational standards, fairness, and regulations. The board of directors, supported by an independent remuneration committee, determines the system. Remuneration includes fixed salaries and performance-based incentives linked to company and individual performance, with annual reviews and transparent communication of any adjustments.

Announcement on the Progress of Providing Guarantees for Subsidiaries

Guangdong Yiyuan Pharmaceutical Co., Ltd. is providing guarantees for its subsidiaries. As of December 16, 2025, the company has provided guarantees totaling 305 million yuan to various banks for Yiyuan Pharmaceutical Co., Ltd. The total external guarantee amount is 936,573.94 million yuan, representing 215.75% of net assets. This announcement updates the progress of these financial commitments.

Announcement on Company's Application for Comprehensive Credit Limit and Subsidiary Guarantee Matters

Notice of the 2025 Annual Shareholders' Meeting

2025 Annual Board of Directors Work Report

2025 Annual Financial Settlement Report

Announcement of Resolutions from the 9th Meeting of the 6th Board of Directors

Announcement on the Profit Distribution Plan for 2025

2026 First Quarter Report

This report details the company's financial performance for the first quarter of 2026. Operating revenue increased by 3.43% to 5,351,016,756.02 yuan. However, net profit significantly decreased to -249,967,562.51 yuan, a 207.35% drop from the previous year. The company's audit committee has reviewed the report, which highlights these material changes in financial results.

Evaluation Report on the Performance of the Accounting Firm for 2025

This report evaluates the accounting firm's 2025 performance, confirming it met regulatory requirements. The firm, established in 1988, served 233 clients, with 1,507 undergoing securities audits. Key figures include project partners Lin Zhi Hua and Li Jian, both registered accountants with strong credibility and independence. The firm demonstrated strong quality management, efficient work performance, and robust information security and risk compliance, successfully meeting expectations.

Report on the Audit Committee's Evaluation of the Accounting Firm's Performance for 2025

Special Report on Non-Operational Fund Occupation and Related Transactions by Rongcheng Accounting Firm

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

This document presents a summary table of non-operating fund occupation and related fund transactions. It outlines details such as the related party, type of fund occupation, amount in RMB, and status. The table is intended to provide transparency on the use of non-operating funds and any associated financial activities. Specific figures and details are not provided in the blank table.

Special Opinion on the Independence Self-Assessment of Independent Directors by Luyan Pharmaceutical Co., Ltd. Board

2025 Annual Audit Report

This report presents the audited financial statements of Yanshan Pharmaceutical Co., Ltd. for the year ended December 31, 2025. The audit was conducted in accordance with Chinese Institute of Certified Public Accountants standards. Key figures show total assets of 388,516,736.00, total liabilities of 631,468,081.18, and total equity of 194,258,368.00. Net profit for 2025 was 53,797,496.71, a decrease from 2024. The financial statements are deemed to comply with regulations and reflect the company's operational status.

2025 Annual Report

Luyan Pharmaceutical Co., Ltd. released its 2025 Annual Report, detailing its financial performance and business operations. The company reported operating income of CNY 21.25 billion, a 3.79% increase year-on-year. However, net profit decreased by 18.74% to CNY 280.88 million. The report highlights a focus on medical devices, which constitute 90.98% of revenue, and outlines strategies for market expansion and operational efficiency amidst potential risks.

Summary of the 2025 Annual Report

This 2025 annual report provides an overview of Shenzhen Medical's operations, financial status, and future plans. Key financial data shows Total Assets at 13,395,732.01 and Total Revenue at 21,216,784.96. The company's primary business involves the production and sale of medical products and services. The report confirms the company has undergone its annual audit and complied with regulations.

Announcement on Utilizing Idle Funds for Entrusted Financial Management

Announcement on Abnormal Fluctuations in Company Stock Trading

Announcement on Abnormal Fluctuations in Company Stock Trading